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tumors affecting the pediatric population. Characteris-
tic microscopic findings most notably include infiltrative 
growth, the invariable presence of oligodendroglioma-
like cellular components, and intense immunolabeling for 
cluster of differentiation 34 (CD34). Moreover, integrative 
molecular profiling reveals a distinct DNA methylation 
signature for PLNTYs, along with frequent genetic abnor-
malities involving either B-Raf proto-oncogene (BRAF) 
or fibroblast growth factor receptors 2 and 3 (FGFR2, 
FGFR3). These findings suggest that PLNTY represents a 
distinct biological entity within the larger spectrum of pedi-
atric, low-grade neuroepithelial tumors.
Keywords Low-grade neuroepithelial tumor · Epilepsy · 
Oligodendroglioma · BRAF · FGFR2 · FGFR3
Abstract Epileptogenic tumors affecting children and 
young adults are a morphologically diverse collection of 
neuroepithelial neoplasms that, as a group, exhibit vary-
ing levels of glial and/or neuronal differentiation. Recent 
advances in molecular profiling technology, including 
comprehensive DNA sequencing and methylation analysis, 
have enabled the application of more precise and biologi-
cally relevant classification schemes to these tumors. In this 
report, we describe a morphologically and molecularly dis-
tinct epileptogenic neoplasm, the polymorphous low-grade 
neuroepithelial tumor of the young (PLNTY), which likely 
accounts for a sizable portion of oligodendroglioma-like 
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Introduction
A diverse array of low-grade neuroepithelial tumors 
(LGNTs) has been associated with epilepsy in children and 
young adults. These neoplasms exhibit varied histopatho-
logic features and glial or glioneuronal differentiation, 
recognized types including pilocytic astrocytoma, diffuse 
astrocytoma (DA), ganglioglioma, pleomorphic xanthoas-
trocytoma (PXA), dysembryoplastic neuroepithelial tumor 
(DNET), angiocentric glioma, and oligodendroglioma [26]. 
Recent large-scale molecular profiling studies have estab-
lished the genomic landscape characterizing the broad 
spectrum of LGNTs, while also pointing toward more 
molecularly uniform disease subgroupings [31, 48]. In par-
ticular, genome-wide DNA methylation profiling and the 
identification of recurrent genomic aberrations (e.g., muta-
tions, rearrangements, and copy number abnormalities) 
have been crucial in the delineation of biologically distinct 
disease entities and in refining tumor classification.
Here, we describe a unique epileptogenic LGNT variant 
affecting children and young adults, which we call poly-
morphous low-grade neuroepithelial tumor of the young 
(PLNTY). We show that PLNTYs, while morphologically 
variable, are uniformly characterized by the presence of 
oligodendroglioma-like cellular components, infiltra-
tive growth patterns, and intense CD34 immunopositivity. 
Moreover, we demonstrate that PLNTYs exhibit a distinct 
DNA methylation signature, most closely related to that of 
ganglioglioma, and harbor molecular abnormalities involv-
ing mitogen-activated protein kinase (MAPK) pathway 
constituents. Our findings suggest that PLNTYs may rep-




Case materials were collected by the authors in the course 
of their hospital or consultative (MKR) practices. Formalin-
fixed and paraffin-embedded (FFPE) tissues were employed 
for all immunohistochemical and molecular diagnostic 
assays. The streptavidin–biotin peroxidase complex method 
was utilized for immunohistochemical studies with anti-
bodies to: glial fibrillary acidic protein (GFAP; Biogenex, 
polyclonal), synaptophysin (SYN; Biogenex, monoclonal), 
neuronal nuclear protein (NeuN; Chemicon, monoclonal), 
neuronal protein HuC/HuD (HuC/HuD; Molecular Probes, 
monoclonal), chromogranin (CHR; Ventana, monoclo-
nal), epithelial membrane antigen (EMA; Sigma/Aldrich, 
monoclonal), CD34 (Ventana, monoclonal), Ki-67 (MIB-1; 
Ventana, monoclonal), isocitrate dehydrogenase 1 (IDH1) 
R132H (Dianova, H09 clone, monoclonal), BRAF V600E 
(Spring Bioscience, monoclonal), α-thalassemia mental 
retardation X-linked (ATRX; Sigma, polyclonal), and oli-
godendrocyte lineage transcription factor 2 (OLIG2; Mil-
lipore, polyclonal).
Mutational genotyping
BRAF V600E mutations were detected using the Seque-
nom Mass ARRAY system as previously described [1].
Fusion transcript detection
Total RNA extracted from FFPE material was analyzed for 
fusion transcripts using anchored multiplex PCR (AMP)-
based methodology (ArcherDx) [49]. Briefly, unidirec-
tional gene-specific primers (GSPs) were used to target 
specific exons in 35 genes frequently involved in chromo-
somal rearrangements. GSPs, in combination with adapter-
specific primers, enriched for known and novel fusion 
transcripts. 220 GSPs ranging from 18 to 39 base pairs in 
length were provided by Archer and are designed either in 
the 5′ or 3′ direction of the corresponding gene.
Genome‑wide DNA methylation profiling
DNA methylation was performed at the NYU molecular 
laboratory and the Genomics and Proteomics Core Facil-
ity of the German Cancer Research Center (DKFZ) using 
the Illumina Infinium HumanMethylation450 (450 k) array 
assessing 482,421 CpG sites (Illumina, San Diego, USA), 
according to the manufacturer’s instructions. DNA methyl-
ation data were normalized by performing background cor-
rection and dye bias correction (shifting of negative control 
probe mean intensity to zero and scaling of normalization 
control probe mean intensity to 10,000, respectively). Fil-
tering of probes included removal of probes targeting the 
X and Y chromosomes (n = 11,551), removal of probes 
containing a single-nucleotide polymorphism (dbSNP132 
Common) within five base pairs of and including the tar-
geted CpG-site (n = 24,536), and probes not mapping 
uniquely to the human reference genome (hg19) allowing 
for one mismatch (n = 9993). To enable future comparabil-
ity, we also removed probes not represented on the updated 
Illumina Infinium HumanMethylationEPIC array. In total, 
428,799 probes were kept for analysis. For unsupervised 
hierarchical clustering, we selected the 2500 probes that 
showed the highest standard deviation across the beta val-
ues. Samples were hierarchically clustered using 1—Pear-
son correlation as a distance measure and average linkage 
as agglomeration method, with unscaled methylation levels 
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shown in a heat map from unmethylated state (blue color) 
to methylated state (red color). Copy number profiles were 
generated using the ‘conumee’ R package in Bioconduc-
tor (http://www.bioconductor.org/packages/release/bioc/
html/conumee.html) and assessed manually for regions of 
interest.
Results
PLNTYs occur in younger patients in association 
with epileptogenic activity, and tend to exhibit a benign 
(WHO grade I) clinical course
We assembled demographic and clinical data for ten 
patients with PLNTYs whose material was examined in the 
Department of Pathology at MSKCC (Table 1). Six patients 
were females and four were males, aged 4-32 (mean = 17.6, 
median = 17.5) years at tissue diagnosis. Only four patients 
were older than 18 years of age and one of these, a 32 year-
old female representing the oldest patient in the cohort at 
diagnosis, had tumor-related symptoms (temporal lobe 
seizures) since 6 years of age. Save for one patient (case 
8) who reportedly had prior resection of a meningioma 
18 years previously, no patient had a history or evidence of 
another neoplastic or syndromic disorder. Excepting two 
patients with occipital lobe lesions, including one patient 
(case 7) who had headaches and dizziness of six days dura-
tion and one patient (case 10) who had a two-year history of 
visual disturbances, all patients suffered refractory epilepsy 
of 1-20 years duration prior to diagnosis.
Seven tumors were situated in the temporal lobes (six 
right and one left), four of which were medially posi-
tioned. One of the latter (case 2) extended into the postero-
lateral thalamus and posterior limb of the internal capsule 
(PLIC). Two of three extratemporal tumors were in the 
right occipital lobe and one was in the right frontal lobe. 
In total, nine of ten lesions were right-sided. Neuroradio-
logic studies were available for review in seven cases. Fea-
tures that would distinguish the lesions under consideration 
from other primary brain tumors or space-occupying pro-
cesses characteristic of this age group were not identified. 
All presented as unifocal regions of FLAIR hyperintensity 
with increased or mixed signal characteristics on T2—
weighted imaging. Maximal recorded dimensions ranged 
from 0.7 to 3 cm. Four exhibited cystic components. Only 
two cases (2 and 6) manifested areas of irregular or nodu-
lar enhancement in post-gadolinium T1—weighted studies 
(Fig. 1a–d) and none were associated with significant mass 
effect or edema. Save for case 2, a tumor centered in the 
right medial temporal lobe with extension into the poste-
rolateral thalamus and PLIC, all lesions were superficially 
situated. Three patients had CT studies, all demonstrating 
lesion-associated calcifications. In two cases (1 and 2), 
tumors remained stable in size over surveillance intervals 
of 12 and 20 months. A third lesion (case 10) demonstrated 
enlargement from 0.7 to 0.9 cm in greatest dimension over 
24 months of observation while a fourth (case 6) remained 
stable over 48 months of surveillance and enlarged slightly 
over an additional 24 months. Neuroradiologic diagnoses 
included glioma, oligodendroglioma, DNET, and focal cor-
tical dysplasia.
Details of treatment and outcome were available for nine 
patients (Table 1). Follow-up intervals ranged from 12 to 89 
(mean = 47) months, with five patients monitored longer 
than 50 months from diagnosis. Of eight patients who had 
gross total tumor resections, all were free of disease at last 
follow-up save for patient six who suffered breakthrough 
seizures 36 months after surgery and was found to have 
a possibly new area of FLAIR signal abnormality at the 
base of the resection cavity. Of the five other patients with 
refractory epilepsy who had gross total excisions, four were 
rendered seizure-free and one had a marked reduction in 
seizure frequency. The single patient (case 2) who under-
went subtotal resection for a tumor extending from the 
temporal lobe to the thalamus and PLIC had stable radio-
graphic disease at 18 months but had developed psychotic 
manifestations (hearing voices, exhibiting hyper-religiosity, 
and aggressive behavior) and attempted suicide.
Despite histopathologic variability, PLNTYs 
are invariably characterized by the presence 
of oligodendroglioma‑like cellular components, 
an infiltrative growth pattern, and intense CD34 
immunopositivity
All ten tumors in our sample set evidenced infiltrative 
growth patterns (many also having more compact regions) 
and harbored oligodendroglioma-like components 
(Fig. 2a, b), these constituting the nearly exclusive popu-
lation in one example (case 1) and dominating three other 
lesions (cases 5, 6, and 7). Exhibiting both intra- and 
inter-tumoral heterogeneity, these ranged from classically 
oligodendrocyte-like elements having uniformly small 
and perfectly rounded nuclei with conspicuous perinu-
clear halo effects to components displaying considerable 
variation in nuclear size, more oval or spindled nuclear 
contours, nuclear membrane wrinkling, grooving, and 
occasional intranuclear pseudoinclusions. In some fields, 
the equidistant distribution of tumor cells in relation to 
stromal capillaries resulted in a vague or more decided 
pseudorosetting (Fig. 2g, h), intraoperative smear prepa-
rations potentially revealing pseudorosetted attachment of 
neoplastic cells to blood vessels as well. Except case 1 all 
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tumors harbored elements of patently astrocytic or cyto-
logically ambiguous aspect also (Fig. 2c, f). The former 
included fibrillary, spindled, and pleomorphic populations 
of varying cell density. Calcifications were identified in 
nine of ten cases, ranging from discrete calcospherules 
to confluent calcific masses with osseous metaplasia. 
Perivascular lymphocytic infiltration was conspicuous 
only in case 1 and possibly related to prior electrode grid 
placement. Notably absent were gemistocytic elements, 
Rosenthal fibers, eosinophilic granular bodies, myxoid 
microcysts, dysmorphic neuronal/ganglion cell forms, 
neurocytic or ependymal rosettes, microvascular prolif-
eration, and necrosis. In no case was a “specific glioneu-
ronal element” of dysembryoplastic neuroepithelial tumor 
type identified. Rare mitoses were found in cases 6 and 7, 
the mitotic rate in other lesions being essentially nil. Two 
lesions (cases 1 and 4) were associated with anomalous 
neuronal clustering in the regional cerebral cortex.
All ten cases assessed exhibited expression of glial 
fibrillary acidic protein (GFAP; Fig. 3a), though this was 
often focal or patchy and only weak cytoplasmic labeling 
characterized three lesions. Areas of pseudorosette forma-
tion demonstrated GFAP-immunoreactive cell processes 
converging on vessel walls. All ten cases studied also mani-
fested both intense and often widespread tumor cell expres-
sion of CD34 as well as the presence in regional cortex of 
ramified, CD34-expressing neural elements in large num-
bers (Fig. 3e, h). In some cases, regions of striking CD34 
expression by neoplastic cells abruptly gave way to areas in 
which tumor cells of identical histological appearance were 
entirely CD34-nonreactive. All nine cases studied exhibited 
widespread OLIG2 expression (Fig. 3b). Three of ten cases 
(1, 2, and 3) demonstrated BRAF V600E expression that 
was relatively weak (Fig. 3d), though mutation was con-
firmed on molecular assessment (see below). One case (10) 
manifested weak matrix labeling for synaptophysin that 
could not be distinguished from background neuroparen-
chymal reactivity. All ten cases were entirely negative for 
expression of HuC/HuD (Fig. 3c), NeuN, chromogranin, 
and IDH1 (R132H), none showing dot- or ring-type EMA 
labeling. All seven cases assessed demonstrated retained 
expression of ATRX. MIB-1/Ki-67 labeling activity was 
negligible in eight of ten cases, being well below 1%. Cases 
6 and 7 harbored microscopic foci in which he MIB-1/
Ki-67 labeling indices rose to 5 and 3%, respectively.
None of the ten tumors assessed exhibited evidence of 
chromosome 1p or 19q deletion by fluorescence in situ 
hybridization (FISH). Case 1 demonstrated 3–4 copies 
of 1p36/1q36 and 19p13/19q13 in 20% and 56% of cells, 
respectively. Case 2 harbored 3-4 copies of 1p36/1q36 and 
19p13/19q13 in 17 and 40% of cells, respectively. Three 
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PLNTYs are characterized by molecular abnormalities 
involving MAP kinase pathway constituents
To identify potential oncogenic driver events in PLNTYs, 
we subjected our sample set to both directed and unsuper-
vised molecular profiling. Given the frequency with which 
molecular abnormalities involving BRAF and other MAP 
kinase pathway components feature in low-grade epi-
leptogenic brain tumors of childhood [21]—particularly 
pilocytic astrocytoma, pleomorphic xanthoastrocytoma 
(PXA), and ganglioglioma—we reasoned that PLNTYs 
might harbor similar events. First, we employed validated 
Fig. 1  Radiographic features 
of PLNTY. Typical appearance 
of a unifocal abnormality best 
seen on FLAIR sequence (a; 
case 1). Frequent calcifications 
appreciated on CT scan (b; case 
2). Focal contrast enhancement 
was seen in two cases (c–f) as 
demonstrated by FLAIR (c, 
d) and T1 post-contrast (e, f) 
images for cases 6 (c, e) and 2 
(d, f). Cystic change was also 
seen in case 6 (c, e)
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Sequenom-based genotyping for BRAF V600E, the most 
common cancer-associated BRAF mutation. Eight of the 
ten cases in our sample set had sufficient material for DNA-
based analyses (Table 1), and within this subset we identi-
fied three tumors with BRAF V600E mutations (Table 1). 
We subsequently confirmed our genotyping findings using 
mutation-specific immunohistochemical staining (Fig. 3d).
We also employed RNA-seq-based methodology 
(ArcherDx) to identify fusion transcripts in six of our 
samples, with the initial aim of assessing whether the 
KIAA1549-BRAF fusion event commonly found in pilo-
cytic astrocytomas [4, 22, 30, 38] exhibits similar preva-
lence in PLNTYs. While we were unable to demonstrate 
KIAA1549-BRAF transcripts in any profiled tumors, 
we identified fusions involving fibroblast growth factor 
receptors, FGFR2 and FGFR3, in three cases (Fig. 4a, b; 
Table 1). Notably, FGFR fusions were mutually exclu-
sive with BRAF V600E mutations across our sample set. 
Two of the identified FGFR fusions, FGFR3-TACC3 and 
FGFR2-KIAA1598, were initially reported in earlier 
Fig. 2  Morphological features 
of PLNTY. Oligodendroglial 
(a, b), fibrillary astrocytic (c, 
d), and spindled astrocytic (e, 
f) features as seen in cases 3 
(a, c, e) and 6 (b, d, f). Vague 
perivascular pseudorosetting (g, 
h) as seen in case 5 by smear 
preparation (g) as well as sec-
tioning (h)
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profiling studies of cholangiocarcinoma, GBM, and pedi-
atric low-grade glioma [16, 18, 39, 48]. Moreover, FGFR3-
TACC3 has been validated as an oncogenic driver in multi-
ple glioma-relevant disease model systems [39].
FGFR fusions are thought to drive enhanced down-
stream signaling through MAP kinase pathway effectors 
by way of homodimerization and autophosphorylation, a 
process mediated by coiled coil domains resident in their 
respective fusion partners (e.g., TACC3, KIAA1598) [16, 
39]. The third fusion transcript identified in our sample 
set, which is novel, pairs FGFR2 with exons 14–18 of 
CTNNA3. Interestingly, while CTNNA3 does not harbor 
coiled coils per se, exons 14–18 encode the entirety of its 
C-terminal dimerization domain required for the stabi-
lization of cell–cell junctions [34]. In this way, FGFR2-
CTNNA3 likely functions in the same manner as other 
previously reported FGFR fusions. Finally, copy number 
profiling derived from Infinium methylation analysis (see 
below) demonstrated that FGFR3 and FGFR2 fusions 
derived from tandem duplication and deletion events, 
Fig. 3  Immunohistochemi-
cal features of PLNTY. Strong 
labeling for GFAP as seen in 
case 3 (a), OLIG2 positivity as 
seen in case 2 (b), negativity for 
HuC/HuD as seen in case 6, and 
expression of BRAF V600E as 
seen in case 3. Diffuse strong 
expression of CD34 in both 
tumor cells (e, f) and peripher-
ally associated ramified neural 
elements (g, h) as seen in case 3 
(e, g) and case 6 (f, h)
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respectively, consistent with prior reports (Fig. 4a, d). 
Moreover, these data revealed an additional likely FGFR2-
KIAA1598 fusion event in a tumor that had not undergone 
ArcherDX analysis (Table 1, case 6). No additional recur-
rent copy number aberrations were identified (FIG. S1).
Genome‑wide methylation profiling segregates PLNTYs 
from other pediatric low‑grade neuroepithelial tumors
To better determine the precise molecular classification of 
PLNTYs and gain insight into their histogenesis, we per-
formed genome-wide DNA methylation analysis on eight 
samples in our cohort using the Infinium MethylationEPIC 
platform. Numerous studies have demonstrated the utility 
of methylation profiling in establishing robust molecular 
taxonomies that often transcend conventional histopatho-
logic designations [20, 27, 31, 40, 41], a process greatly 
facilitated by a large existing repository of brain tumor 
array data maintained at the German Cancer Research 
Center (DFKZ). Examining our methylation findings in 
the context of this database, we found that PLNTYs exhib-
ited a distinct signature, most closely related to gangli-
ogliomas, with similarities to pilocytic astrocytomas and 
DNETs as well (Fig. 5). Importantly, BRAF alterations 
(V600E mutations and KIAA1549-BRAF fusions) were 
distributed across multiple diagnostic groups—PLNTY, 
ganglioglioma, and pilocytic astrocytoma—each of which 
exhibited a distinct methylation signature. More distant 
associations with other neuroepithelial tumor entities, 
including PXA, IDH-mutant diffuse astrocytoma and oligo-
dendroglioma, and pediatric low-grade glioma with MYB/
MYBL1 alterations were revealed by t-sne scatterplot-
ting (FIG. S2). Our analysis also revealed two additional 
cases among previously profiled tumors, histopathologi-
cally classified as ganglioglioma and “low-grade glioma”, 
which clustered with the PLNTY methylation signature. 
Fig. 4  FGFR fusions in PLNTY. Schematics showing the tan-
dem duplication and deletion events resulting in FGFR3-TACC (a), 
FGFR2-KIAA1598 (b), and FGFR2-CTNNA3 (b) fusions. c Copy 
number profiles from chromosome 10 showing causative dele-
tion events for FGFR2-KIAA1598 (upper) and FGFR2-CTNNA3 
(lower) fusions in two ArcherDx-confirmed cases (5 and 7). Red and 
green indicate relative copy number loss and gain respectively. The 
genomic positions of CTNNA3, KIAA1598, and FGFR2 are indicated. 
d Both fusion events are recapitulated in two additional cases identi-
fied in the DFKZ database. In the case of the likely FGFR2-CTNNA3 
fusion (lower), noise precludes definitive segmentation of the deletion 
event (blue line)
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Interestingly, these tumors harbored likely FGFR2 fusions 
by copy number analysis (Fig. 4c, d). Taken together, these 
findings suggest that PLNTYs are a distinct biological 
entity related to other low-grade neuroepithelial neoplasms 
primarily affecting children and young adults.
Discussion
LGNTs of children and young adults are a heterogeneous 
group of neoplastic entities whose fundamental identities 
reflect both molecular and histogenic factors. In recent 
years, comprehensive genomic profiling in large patient 
cohorts has confirmed the biological distinctiveness of 
some well-established histopathologic variants, such as 
pilocytic astrocytoma, PXA, and angiocentric glioma [3, 4, 
22, 30, 31, 33, 38, 48]. However, other morphological sub-
types, including oligodendroglial tumors, have exhibited 
more variable molecular features, implying the underlying 
existence of multiple distinct disease entities. In this study, 
we sought to characterize a specific oligodendroglioma-
like LGNT with characteristic clinical behavior, locali-
zation, and histopathology. We found that these tumors 
form a cohesive biological subgroup characterized by 
intense CD34 expression, molecular abnormalities involv-
ing MAPK signaling, and a distinct DNA methylation 
signature.
The designation of PLNTYs as “polymorphous” is 
meant to acknowledge the fact that, while all harbored 
components prompting consideration of oligodendro-
glioma in the differential diagnosis, most also contained 
populations of patently astrocytic or ambiguous appear-
ance and several manifested foci of vague or more fully 
developed perivascular pseudorosetting that raised ques-
tion of ependymocytic differentiation. Consistent expres-
sion of GFAP and OLIG2 in the absence of dot- or 
ring-type EMA labeling and failure to express neuronal 
“markers” would argue for these lesions fundamentally 
representing non-ependymal gliomas. However, we think 
it prudent to reserve final judgment on their fundamental 
differentiating capacity and so refer to these generically as 
“neuroepithelial”. The issue of their molecular relationship 
to gangliogliomas is further addressed below. There can 
be little doubt that the neoplasms of the PLNTY group are 
part of a larger family of tumors reported as diffuse astro-
cytomas or oligodendrogliomas of pediatric type having 
Fig. 5  Global methylation profiling delineates PLNTY from other 
epileptogenic tumors of children and young adults. Heat map (red 
increase methylation, blue decreased methylation) showing distinct 
CpG methylation signature for PLNTY. Histopathologic and genetic 
correlates are shown. GG ganglioglioma, PA pilocytic astrocytoma, 
DNET dysembryoplastic neuroepithelial tumor, LGG NOS low-grade 
glioma, not otherwise specified. Red squares indicate DFKZ samples 
not in the original MSKCC cohort
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MAPK pathway-activating genetic abnormalities [31, 
48]. Similarly, the lesions we describe as PLNTYs would 
appear to lie among CD34-expressing neoplasms con-
stituting a subset of growths for which Blumcke and col-
leagues have proposed the designation “long-term epilepsy 
associated tumors” (LEATs) [7]. Whatever terminology is 
eventually employed, the designation of PLNTYs should 
clearly segregate them from the ineluctably recurring and 
genetically distinct gliomas of infiltrating type encoun-
tered in generally older patients.
A constant and striking feature of our tumors was 
intense, frequently widespread expression of CD34 by 
tumor cells and by ramified neural elements in the regional 
cerebral cortex. In fact, it was this immunohistochemical 
observation, along with the consistent failure of the tumors 
in this series to manifest labeling for IDH1 R132H or 
chromosome 1p/19q codeletion, despite their oligodendro-
gliomatous appearances, that prompted us to consider these 
as distinct from the infiltrating gliomas of later life and to 
initiate additional molecular studies. While the immunohis-
tochemical labeling of some glioblastomas for CD34 is rec-
ognized [19, 25], this phenomenon is generally foreign to 
infiltrating astrocytomas of lower grade and to neoplasms 
of the oligodendroglioma group [2, 5, 6, 10, 13–15, 28, 29, 
32, 36, 43, 45–47]. Only one of the many studies that have 
examined CD34 expression in gliomas found tumoral (as 
opposed to endothelial) immunoreactivity in lesions clas-
sified as WHO grade II or III astrocytomas, oligodendro-
gliomas or oligoastrocytomas [8]. Of note, and empha-
sized by the authors of this single outlier, such reactivity 
was confined to examples deriving from the temporal lobes 
of patients with chronic and refractory seizures whereas 
“tumor samples derived from non-epileptic patients with 
lesions outside the temporal lobe never showed CD34 
-immunoreactive neural cells” [8]. It is likely that at least 
some of these ostensibly conventional gliomas represented 
neoplasms of the type we describe.
In addition to distancing lesions of the PLNTY group 
from conventional “adult-type” gliomas of the infiltrating 
variety (a matter of great practical import given that the 
latter are rarely curable by surgical or adjuvant means, are 
prone to progression and eventually fatal in the great major-
ity of cases), shared CD34 expression may well reflect a 
link between PLNTYs and other tumors long recognized 
for their association with chronic epilepsy in young sub-
jects. Specifically, expression of CD34 is a common attrib-
ute of pediatric gangliogliomas [8–10, 17] and PXAs [17, 
35], having also been recorded by some observers in the 
setting of DNET [42, 44]. There is, furthermore, a strong 
association of these epileptogenic tumors with the presence 
in regional cortical tissues of the ramified, CD34- express-
ing neural elements observed in complex with each of our 
cases. Foreign to the normal human brain, these have also 
been found in association with glioneuronal microhamarto-
mas (“hamartia”) and some forms of cortical dysplasia [8, 
17]. The transient expression of CD34 in the murine neu-
ral tube [12, 24] has elicited speculation that these rami-
fied cells represent developmentally arrested/dysregulated 
neural progenitors that testify to regional dysontogenesis 
and that may give rise to the CD34-expressing tumors with 
which they are identified [8–10]. The superficial position-
ing of the neoplasms reported here, their predilection for 
the temporal lobes, presentation in the young, association 
with chronic epilepsy, general indolence, CD34 expression, 
MAPK pathway-activating genetic lesions and methyla-
tion profiles would all support a link to the pediatric gan-
glioglioma and other “developmental” tumors. In fact, it 
could be argued that the tumors of our PLNTY group rep-
resent “lopsided” variants of ganglioglioma in which neu-
ronal components and even immunophenotypic evidence of 
neuronal differentiation may not be demonstrable, though 
whether these ostensibly infiltrative lesions are as biologi-
cally stable and surgically curable as classical ganglioglio-
mas remain to be seen.
Using focused molecular profiling, we found that nearly 
all of the PLNTYs harbored either BRAF V600E muta-
tions or fusion events involving FGFR2/FGFR3. These 
abnormalities occurred in a mutually exclusive fashion, 
consistent with the notion that shared downstream molec-
ular sequelae fundamentally drive the pathogenesis of 
PLNTYs. Indeed, both V600E-mutant BRAF monomers 
and FGFR fusion chimeras have been shown to activate 
MAPK signaling, the latter by way of constitutive recep-
tor dimerization [16, 39], a mechanism likely operative in 
all such cases in our sample set (see above). That being 
said, abnormal MAPK pathway activation, by either BRAF 
V600E or FGFR fusion, is hardly specific to PLNTYs as 
a transforming molecular event. BRAF V600E has been 
widely implicated in the pathogenesis of LGNTs, with 
particularly high rates of incidence in gangliogliomas and 
PXAs [37]. Similarly, recent work has identified frequent 
FGFR fusion events in DNETs, and diffusely infiltrating 
pediatric gliomas exhibiting either astrocytic or oligoden-
droglial histopathology [31]. As stated above, we believe 
that PLNTYs likely represent a subset of this latter group. 
BRAF V600E mutations and FGFR fusions are even found 
in a small minority of glioblastomas [11]. Notably, none 
of the tumors in our sample cohort harbored KIAA1549-
BRAF fusions, which are commonly associated with pilo-
cytic astrocytomas and were recently reported in a small set 
of two neoplasms classified as “pediatric oligodendroglio-
mas” [23]. The broad spectrum of brain tumors exhibiting 
MAPK pathway activation attests to its importance as an 
oncogenic mechanism, while also indicating that its precise 
transformative consequences are highly dependent on bio-
logical context.
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Over the past several years, genome-wide DNA methyl-
ation profiling has become an influential tool informing the 
classification of primary brain tumors. For instance, meth-
ylation signatures have been repeatedly utilized to estab-
lish endogenous subclasses within morphologically based 
disease entities, most notably for glioblastoma and medul-
loblastoma [20, 41]. Methylation profiling has also facili-
tated more appropriate tumor classification within poorly 
defined histopathologic groupings. In a recent study of 
supratentorial primitive neuroectodermal tumors (PNETs), 
methylation arrays delineated the vast majority of sampled 
neoplasms into other more well-established diagnostic cat-
egories, including glioblastoma and ependymoma [40]. In 
these respects, specific patterns of CpG island methylation 
capture the biological distinctiveness of a given neoplastic 
process. In our analysis, PLNTYs exhibited a unique DNA 
methylation signature whose distinctiveness even allowed 
the identification of additional cases from a much larger 
sample cohort that had already been subjected to profil-
ing. Interestingly, the PLNTY methylation signature was 
most closely related to those of other, morphologically 
diverse LGNTs—gangliogliomas, pilocytic astrocytomas, 
and DNETs—characterized by MAPK pathway activation. 
This finding implies that the unique aspects of the PLNTY 
methylation signature relate to issues of histogenesis and 
differentiation state rather than the primary oncogenic 
driver mechanism.
Applying our findings to the diagnostic setting, several 
considerations should be kept in mind. While the demon-
stration of aberrant CD34 expression by neoplastic and 
ramified neural elements certainly suggests PLNTY in 
the appropriate context, calling into serious question the 
diagnosis of any conventional glioma of infiltrating type, 
it would be premature to conclude that this finding obvi-
ates the need for assessments of IDH1/2 mutation and 
chromosome 1p/19q codeletion status in the evaluation of 
neurosurgical specimens. In a similar vein, CD34 expres-
sion cannot be proposed as a surrogate marker of MAPK 
pathway activation at this time. Candidate cases should be 
studied for BRAF and FGFR2/3 abnormalities and an inte-
grated diagnosis rendered on the basis of the histologic, 
immunophenotypic, and molecular genetic features. In 
fact, we believe that ostensibly infiltrating glial neoplasms 
deriving from young individuals (especially those posing as 
chromosome 1p/19q non-codeleted oligodendrogliomas) 
should be assessed in similar fashion irrespective of CD34 
expression status, as the CD34-labeling tumors we describe 
may constitute but a subset of fundamentally unified neu-
roepithelial neoplasms sharing a spectrum of MAPK 
pathway-activating genetic lesions. In this connection, we 
would point out that the “pediatric oligodendrogliomas” 
(and other low-grade gliomas of the young) reported to 
date as displaying BRAF and FGFR abnormalities seem 
not to have been systematically studied for CD34 expres-
sion [23, 31, 48].
In summary, we report the characterization of PLNTY, 
a molecularly distinct LGNT that likely represents a sig-
nificant subset of oligodendroglioma-like tumors arising 
in pediatric populations. PLNTYs exhibit an almost invari-
ably benign clinical course and appear to be well controlled 
by gross total resection. Moreover, their driving molecular 
alterations, which uniformly activate MAPK signaling, are 
potentially targetable with existing small molecular inhibi-
tors, providing additional therapeutic options for affected 
patients.
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